Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001628280-25-059014
Filing Date
2025-12-29
Accepted
2025-12-29 16:45:57
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3039
2 EX-99 table_iix20251229.pdf EX-99 240865
  Complete submission text file 0001628280-25-059014.txt   336715
Mailing Address C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116
Business Address C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 (617) 425-9200
MPM BioVentures 2014 (B), L.P. (Reporting) CIK: 0001609493 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144

Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Subject) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-40366 | Film No.: 251609764
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)